Reactive arthritis occurring after COVID-19 infection: a narrative review.
COVID-19
Non-steroidal anti-inflammatory drugs
Oligoarthritis
Reactive arthritis
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
04
02
2022
accepted:
15
05
2022
pubmed:
3
6
2022
medline:
31
1
2023
entrez:
2
6
2022
Statut:
ppublish
Résumé
Reactive arthritis is acute aseptic arthritis occurring 1 to 4 weeks after a distant infection in a genetically predisposed individual. It may occur after COVID-19 infection. We summarize, in this article, the current findings of reactive arthritis following COVID-19 infection. A literature search has been performed from December 2019 to December 2021. We included case reports of reactive arthritis occurring after COVID-19 infection. We collected demographic, clinical, and paraclinical data. A total of 22 articles were reviewed. There were 14 men and 11 women with a mean age of 44.96 + 17.47 years. Oligoarticular involvement of the lower limbs was the most frequent clinical presentation. The time between arthritis and COVID infection ranged from 6 to 48 days. The diagnosis was based on clinical and laboratory findings. The pharmacological management was based on non-steroidal anti-inflammatory drugs in 20 cases. Systemic or local steroid therapy was indicated in 13 patients. Sulfasalazine was indicated in two cases. Alleviation of symptoms and recovery were noted in 22 cases. The mean duration of the clinical resolution was 16 + 57 days. The diagnosis of reactive arthritis should be considered in patients with a new onset of arthritis following COVID-19 infection. Its mechanism is still unclear.
Identifiants
pubmed: 35655110
doi: 10.1007/s15010-022-01858-z
pii: 10.1007/s15010-022-01858-z
pmc: PMC9162104
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Sulfasalazine
3XC8GUZ6CB
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-45Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
García-Kutzbach A, Chacón-Súchite J, García-Ferrer H, Iraheta I. Reactive arthritis: update 2018. Clin Rheumatol. 2018;37(4):869–74.
doi: 10.1007/s10067-018-4022-5
Schmitt SK. Reactive arthritis. Infect Dis Clin North Am. 2017;31(2):265–77.
doi: 10.1016/j.idc.2017.01.002
Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13(4–5):546–9.
doi: 10.1016/j.autrev.2014.01.005
Slouma M, Chammakhi M, Dhahri R, Metoui L, Boussetta N, Ajili F, et al. Unusual evolution of reactive arthritis induced by BCG therapy. Therapie. 2019;74(6):685–8.
doi: 10.1016/j.therap.2019.01.011
Eastin C, Eastin T. Clinical characteristics of coronavirus disease 2019 in China. J Emerg Med. 2020;58(4):711–2.
doi: 10.1016/j.jemermed.2020.04.004
Fragata I, Mourão AF. Coronavirus disease 19 (COVID-19) complicated with post-viral arthritis. Acta Reumatol Port. 2020;45(4):278–80.
Alivernini S, Cingolani A, Gessi M, Paglionico A, Pasciuto G, Tolusso B, et al. Comparative analysis of synovial inflammation after SARS-CoV-2 infection. Ann Rheum Dis. 2020;6:annrheumdis2020 218315.
Houshmand H, Abounoori M, Ghaemi R, Bayat S, Houshmand G. Ten-year-old boy with atypical COVID-19 symptom presentation: a case report. Clin Case Rep. 2020;9:304–8. https://doi.org/10.1002/ccr3.3521 (Epub ahead of print. PMID: 33362924; PMCID: PMC7753279).
doi: 10.1002/ccr3.3521
Talarico R, Stagnaro C, Ferro F, Carli L, Mosca M. Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatol. 2020;2(9):e518–9.
doi: 10.1016/S2665-9913(20)30216-2
Kuschner Z, Ortega A, Mukherji P. A case of SARS-CoV-2-associated arthritis with detection of viral RNA in synovial fluid. J Am Coll Emerg Physicians Open. 2021;2:e12452.
Saikali W, Gharib S. The first non-radiographic axial spondyloarthrits with COVID-19. Immun Inflamm Dis. 2021. https://doi.org/10.1002/iid3.448 .
doi: 10.1002/iid3.448
Cincinelli G, Di Taranto R, Orsini F, Rindone A, Murgo A, Caporali R. A case report of monoarthritis in a COVID-19 patient and literature review: Simple actions for complex times. Medicine (Baltimore). 2021;100:e26089.
doi: 10.1097/MD.0000000000026089
De Stefano L, Rossi S, Montecucco C, Bugatti S. Transient monoarthritis and psoriatic skin lesions following COVID-19. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-218520 .
doi: 10.1136/annrheumdis-2020-218520
Ursini F, Ruscitti P, D’Angelo S, Cacciapaglia F, De Angelis R, Campochiaro C, et al. Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 and Autoimmune systemic disease Italian study group. Ann Rheum Dis. 2021;80(11):1498–501.
doi: 10.1136/annrheumdis-2021-220606
Liew IY, Mak TM, Cui L, Vasoo S, Lim XR. A case of reactive arthritis secondary to coronavirus disease 2019 infection. JCR J Clin Rheumatol. 2020;26(6):233–233.
doi: 10.1097/RHU.0000000000001560
Schenker HM, Hagen M, Simon D, Schett G, Manger B. Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. Rheumatology. 2021;60(1):479–80.
doi: 10.1093/rheumatology/keaa689
Saricaoglu EM, Hasanoglu I, Guner R. The first reactive arthritis case associated with COVID-19. J Med Virol. 2021;93(1):192–3.
doi: 10.1002/jmv.26296
Ono K, Kishimoto M, Shimasaki T, Uchida H, Kurai D, Deshpande GA, et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020;6:e001350.
doi: 10.1136/rmdopen-2020-001350
Sureja NP, Nandamuri D. Reactive arthritis after SARS-CoV-2 infection. Rheumatol Adv Pract. 2021;5:rkab001. https://doi.org/10.1093/rap/rkab001 (Published 2021 Feb 4).
doi: 10.1093/rap/rkab001
Hønge BL, Hermansen MLF, Storgaard M. Reactive arthritis after COVID-19. BMJ Case Rep. 2021;14:e241375.
doi: 10.1136/bcr-2020-241375
Shokraee K, Moradi S, Eftekhari T, Shajari R, Masoumi M. Reactive arthritis in the right hip following COVID-19 infection: a case report. Trop Dis Travel Med Vaccines. 2021;7(1):18.
doi: 10.1186/s40794-021-00142-6
Coath FL, Mackay J, Gaffney JK. Axial presentation of reactive arthritis secondary to COVID-19 infection. Rheumatol Oxf Engl. 2021;20:keab009.
Danssaert Z, Raum G, Hemtasilpa S. Reactive arthritis in a 37-year-old female with SARS-CoV2 infection. Cureus. 2020;12:e9698.
Sinaei R, Pezeshki S, Parvaresh S, Sinaei R, Shiari R, Hassas Yeganeh M, et al. Post SARS-CoV-2 infection reactive arthritis: a brief report of two pediatric cases. Pediatr Rheumatol. 2021;19(1):89.
doi: 10.1186/s12969-021-00555-9
Jali I. Reactive arthritis after COVID-19 infection. Cureus. 2020;12:e11761.
Parisi S, Borrelli R, Bianchi S, Fusaro E. Viral arthritis and COVID-19. Lancet Rheumatol. 2020;2: e655.
doi: 10.1016/S2665-9913(20)30348-9
Di Carlo M, Tardella M, Salaffi F. Can SARS-CoV-2 induce reactive arthritis? Clin Exp Rheumatol. 2021;128:25–6.
Salvatierra J, Martínez-Peñalver D, Salvatierra-Velasco L. COVID-19 related dactyitis. Joint Bone Spine. 2020;87(6):660.
doi: 10.1016/j.jbspin.2020.06.009
Kocyigit BF, Akyol A. Reactive arthritis after COVID-19: a case-based review. Rheumatol Int. 2021;41(11):2031–9.
doi: 10.1007/s00296-021-04998-x
Ouedraogo F, Navara R, Thapa R, Patel KG Reactive arthritis post-SARS-CoV-2. Cureus. 2021 Sep 20 [cited 2022 May 8]. Available from: https://www.cureus.com/articles/64634-reactive-arthritis-post-sars-cov-2
Gasparotto M, Framba V, Piovella C, Doria A, Iaccarino L. Post-COVID-19 arthritis: a case report and literature review. Clin Rheumatol. 2021;40:3357–62.
doi: 10.1007/s10067-020-05550-1
Apaydin H, Guven SC, Kucuksahin O, Omma A, Erten S. A case of human leukocyte antigen B27 positive reactive arthritis associated with severe acute respiratory syndrome coronavirus 2 infection. North Clin Istanb. 2021;8:423–4.
Yokogawa N, Minematsu N, Katano H, Suzuki T. Case of acute arthritis following SARS-CoV-2 infection. Ann Rheum Dis. 2021;80:e101–e101.
doi: 10.1136/annrheumdis-2020-218281
Ghauri MI, Mukarram MS, Riaz K, Syeda U. Post covid-19 reactive arthritis: an emerging existence in the spectrum of musculoskeletal complications of SARSCoV-2 infection. Int J Clin Rheumatol. 2020;0:198.
Colatutto D, Sonaglia A, Zabotti A, Cereser L, Girometti R, Quartuccio L. Post-COVID-19 arthritis and sacroiliitis: natural history with longitudinal magnetic resonance imaging study in two cases and review of the literature. Viruses. 2021;13:1558.
doi: 10.3390/v13081558
El Hasbani G, Jawad A, Uthman I. Axial and peripheral spondyloarthritis triggered by sars-cov-2 infection: a report of two cases. Reumatismo. 2021;73:59–63.
doi: 10.4081/reumatismo.2021.1374
Sieper J, Braun J, Kingsley GH. Report on the fourth international workshop on reactive arthritis. Arthritis Rheum. 2000;43:720–34.
doi: 10.1002/1529-0131(200004)43:4<720::AID-ANR2>3.0.CO;2-8
Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31.
doi: 10.1136/ard.2010.133645
Kingsley G, Sieper J. Third international workshop on reactive arthritis. 23–26 september 1995, Berlin, Germany report and abstracts. Ann Rheum Dis. 1996;55:564–84.
doi: 10.1136/ard.55.8.564
Bekaryssova D, Yessirkepov M, Zimba O, Gasparyan AY, Ahmed S. Reactive arthritis before and after the onset of the COVID-19 pandemic. Clin Rheumatol. 2022;41:1641–52.
doi: 10.1007/s10067-022-06120-3
Zeidler H. Post-COVID‑19-Arthritis. Manifestation unter dem klinischen Bild einer reaktiven Arthritis. Z Für Rheumatol. 2021 Jul 9 [cited 2021 Jul 27]. Available from: https://link.springer.com/ https://doi.org/10.1007/s00393-021-01045-9
Wendling D, Prati C, Chouk M, Verhoeven F. Reactive arthritis: treatment challenges and future perspectives. Curr Rheumatol Rep. 2020;22:29.
doi: 10.1007/s11926-020-00904-9
Ruiz-Galiana J, De Lucas RP, García-Botella A, García-Lledó A, Gómez-Pavón J, González Del Castillo J, et al. Persistence and viability of SARS-CoV-2 in primary infection and reinfections. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter. 2022;35:1–6.
Sharma V, Sharma A. Infectious mimics of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022;36:101736.
doi: 10.1016/j.berh.2021.101736
Kanduc D, Shoenfeld Y. On the molecular determinants of the SARS-CoV-2 attack. Clin Immunol. 2020;1:108426.
doi: 10.1016/j.clim.2020.108426
Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2022;94:54–62.
doi: 10.1002/jmv.27292
Allen RL, Gillespie GM, Hall F, Edmonds S, Hall MA, Wordsworth BP, et al. Multiple T cell expansions are found in the blood and synovial fluid of patients with reactive arthritis. J Rheumatol. 1997;24:1750–7.
Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130:2202–5.
doi: 10.1172/JCI137647
Chaurasia S, Shasany AK, Aggarwal A, Misra R. Recombinant Salmonella typhimurium outer membrane protein A is recognized by synovial fluid CD8 cells and stimulates synovial fluid mononuclear cells to produce interleukin (IL)-17/IL-23 in patients with reactive arthritis and undifferentiated spondyloarthropathy. Clin Exp Immunol. 2016;185:210–8.
doi: 10.1111/cei.12799
Wendling D, Prati C, Chouk M, et al. Reactive arthritis: treatment challenges and future perspectives. Curr Rheumatol Rep. 2020;22:29.
doi: 10.1007/s11926-020-00904-9
Kilinc D, van de Pasch S, Doets AY, Jacobs BC, van Vliet J, Garssen MPJ. Guillain-Barré syndrome after SARS-CoV-2 infection. Eur J Neurol. 2020;27:1757–8.
doi: 10.1111/ene.14398
Gokhale Y, Patankar A, Holla U, Shilke M, Kalekar L, Karnik ND, et al. Dermatomyositis during COVID-19 pandemic (a case series): is there a cause effect relationship? J Assoc Physicians India. 2020;68:20–4.
Jacobs J, Eichbaum Q. COVID-19 associated with severe autoimmune hemolytic anemia. Transfusion (Paris). 2021;61:635–40.
doi: 10.1111/trf.16226
Shah S, Danda D, Kavadichanda C, Das S, Adarsh MB, Negi VS. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol Int. 2020;40:1539–54.
doi: 10.1007/s00296-020-04639-9
Derksen VFAM, Kissel T, Lamers-Karnebeek FBG, van der Bijl AE, Venhuizen AC, Huizinga TWJ, et al. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis. 2021;1:annrheumdis 2021 219859.
Perrot L, Hemon M, Busnel JM, Muis-Pistor O, Picard C, Zandotti C, et al. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021;3:e6-8.
doi: 10.1016/S2665-9913(20)30396-9
Slouma M, Mhemli T, Abbes M, Triki W, Dhahri R, Metoui L, et al. Rheumatoid arthritis occurring after coronavirus disease 2019 (COVID-19) infection: case based review. Egypt Rheumatol. 2022;44:275–8.
doi: 10.1016/j.ejr.2022.03.001
Roongta R, Chattopadhyay A, Ghosh A. Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’ Ann Rheum Dis. 2021 Apr 27 [cited 2021 Jul 25]. Available from: https://ard.bmj.com/content/early/2021/04/26/annrheumdis-2021-220479
Baimukhamedov C, Barskova T, Matucci-Cerinic M. Arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021;3:e324–5.
doi: 10.1016/S2665-9913(21)00067-9
Maggi E, Azzarone BG, Canonica GW, Moretta L. What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy. 2022;77:1114–28.
doi: 10.1111/all.15112
del LópezGonzález MC, PeralGarrido ML, Calabuig I, TovarSugrañes E, Jovani V, Bernabeu P, et al. Case series of acute arthritis during COVID-19 admission. Ann Rheum Dis. 2021;80:e58–e58.
doi: 10.1136/annrheumdis-2020-217914
Alivernini S, Cingolani A, Gessi M, Paglionico A, Pasciuto G, Tolusso B, et al. Comparative analysis of synovial inflammation after SARS-CoV-2 infection. Ann Rheum Dis. 2021;80:e91–e91.
doi: 10.1136/annrheumdis-2020-218315
Hase R, Kurata R, Ishida K, Kurita T, Muranaka E, Mito H. Acute gouty arthritis during favipiravir treatment for coronavirus Disease 2019. Intern Med Tokyo Jpn. 2020;59(18):2327–9.
doi: 10.2169/internalmedicine.5377-20
Hojjati SMM, Heidari B, Babaei M. Development of rheumatoid arthritis during treatment of multiple sclerosis with interferon beta 1-a. Coincidence of two conditions or a complication of treatment: a case report. J Adv Res. 2016;7:611–3.
doi: 10.1016/j.jare.2016.06.004
Toussirot E, Béreau M, Bossert M, Malkoun I, Lohse A. Occurrence of psoriatic arthritis during interferon beta 1a treatment for multiple sclerosis. Case Rep Rheumatol. 2014;2014: 949317.